SCHEMBL29327818

SCHEMBL29327818

CCc1ccc(-c2nc3cc(NC(=O)c4cc(C#N)cnc4S(C)(=O)=O)ccc3o2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 9/20 0.70
▸ MAPT P10636 5/20 0.56
▸ TP53 P04637 4/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ POLB P06746 2/20 0.55
▸ CYP2C8 P10632 2/20 0.53
▸ NR1I2 O75469 1/20 0.53
▸ PPARD Q03181 1/20 0.53
▸ PPARA Q07869 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.53
▸ NPC1 O15118 1/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ CETP P11597 2/20 0.48
▸ PTPN2 P17706 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ PTPN5 P54829 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327844 0.93 PPARG (0.60) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327807 0.91 PPARG (0.56) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327840 0.90 PPARG (0.57) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327587 0.87 PPARG (0.77) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29328005 0.86 PPARG (0.58) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29328003 0.86 PPARG (0.52) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327801 0.85 MAPT (0.56) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327833 0.85 PPARG (0.55) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327820 0.85 MAPT (0.55) PPARGMAPTTP53RXFP1NPC1
SCHEMBL29327747 0.84 PPARG (0.62) PPARGMAPTTP53SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885MAPT 4591/4885TP53 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback